# GLP-1 weight drug side effects create new beauty and nutrition market 2026-08-21T00:36:06+00:00 | Business & Economy | Indian Opinion Desk Corroboration: 2 independent outlets Indian companies are racing to launch protein-rich foods, collagen supplements and face fillers to capitalise on side effects from the growing use of GLP-1 weight-loss drugs such as Ozempic and Mounjaro. Rapid weight loss from these prescription medicines depletes facial volume, skin elasticity, and protein and fibre levels, creating new demand in both nutrition and beauty. Nestle India, through its joint venture with Dr. Reddy's Laboratories, has introduced Celevida GLP+, a nutrition supplement for people on GLP-1 therapy. Tata Consumer Products is preparing to enter waters and snacks with protein and fibre, with managing director Sunil D'Souza saying the company will start launching products across multiple categories in the next 60 days. Sugar Cosmetics and HUL's Lakme are promoting non-invasive make-up alternatives such as lip fillers. Radhika Ghai, founder of Kindlife, called this demand the biggest new driver beauty has had in a decade, growing with the patient base rather than fading seasonally. ## Indian Opinion Analysis The coverage is uniform straight business reporting, with both outlets using identical quotes and information. The story is a classic demand-shift tale: GLP-1 drugs create side effects, which create a new consumer market. The measured middle-ground read is that this is a real market signal, Tata and Nestle's joint venture with Dr. Reddy's are concrete moves, but the market is nascent and the consumer base tied to prescription growth. Sugar Cosmetics and Lakme's 'lip fillers' are non-invasive make-up, not medical procedures, a nuance easy to overstate. Watch the next 60 days for Tata's product launch. ## Coverage Coverage: 2 sources, 2 neutral - economictimes.indiatimes.com (neutral report) Straight business story with no government angle, details corporate responses and market trends - timesofindia.indiatimes.com (neutral report) Same wire-level coverage with identical quotes and structure, neutral on policy This story was synthesised by AI from the 2 sources linked above. Updated: this story now draws on 2 sources. Last updated 2026-08-21T08:41:43+00:00. Tags: Dr Reddy's Laboratories, GLP-1 drugs, Hindustan Unilever, Nestlé India, Sugar Cosmetics, Tata Consumer Products Canonical: https://indianopinion.org/glp-1-weight-loss-drugs-spark-new-india-market-for-side-effect-products/ License: Summary and commentary (c) Indian Opinion, reusable with attribution. Facts belong to the linked sources. Cite: https://indianopinion.org/glp-1-weight-loss-drugs-spark-new-india-market-for-side-effect-products/#story-in-brief How this brief was made: an AI model read the reports linked above and wrote this summary and analysis, which were published automatically. Published briefs are sampled every hour by an automated quality check; the editor verifies its findings and approves corrections, and corrected briefs carry a dated correction line. Stance labels are editorial classifications of how each outlet framed this story, assigned by the same model, not ratings of the outlets. We do no original reporting. Methodology: https://indianopinion.org/ai-use-policy/